CD83 and coronary artery disorder: CAD patients with CAE were detected to have significantly higher levels of certain activation markers such as CD11b (44.5 ± 5.0 versus 30.0 ± 3.8 and 20.9 ± 3.6), CD11c, (96.3 ± 10.9 versus 66.1 ± 6.4 and 50.4 ± 5.7) CD54 (45.6 ± 6.7 versus 31.1 ± 4.9 and 20.8 ± 3.2), CD83 (44.6 ± 6.1 versus 30.8 ± 2.4 and 25.6 ± 2.8), CD86 (50.7 ± 5.0 versus 39.2 ± 4.1 and 29.5 ± 4.1) and MHC Class II (112.4 ± 11.3 versus 73.1 ± 9.5 and 54.5 ± 4.5) molecules on the surface of mDCs in comparison to CAD patients without CAE and normal subjects with angiographically normal coronary arteries (Figure 1).